The global ovarian cancer drugs market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing number of women diagnosed with ovarian cancer and the rising awareness about its symptoms. The major factors driving this market are the increasing number of women diagnosed with ovarian cancer and the rising awareness about its symptoms.
Alkylating agents are one type of drug used for treating ovarian cancer, which is expected to grow at a CAGR of 6% during the forecast period, from 2021 to 2030. Mitotic inhibitors are another type that is used for treating ovarian cancer and it is expected to grow at a CAGR of 4% during the forecast period, from 2021 to 2030. Antirheumatics are also used for treating ovarian cancer and it is expected to grow at a CAGR of 3% during the forecast period, from 2021-2030. Antipsoriatics are also used for treating ovarian cancer and it is expected to grow at a CAGR of 2% during the forecast period, from 2021-2030. VEGF/VEGFR inhibitors are another type that can be used for treating ovarian cancers; they have been approved by FDA in 2018 and they will be available in 2020; these drugs will be able to treat cancers that have not responded well or have progressed after treatment with other types; these drugs will be able increase survival rates by up 10%. PARP inhibitors can also be used as treatments against cancers such as ovaries; these drugs were approved by FDA in 2017 but their availability date has not been announced yet; these drugs work by blocking an enzyme called PARP which helps cells repair themselves after DNA damage occurs due chemotherapy or radiation therapy treatments; PARP inhibitors can help prevent tumor cells from repairing themselves so they die off more quickly than normal cells do when exposed chemotherapy or radiation therapy treatments.
Some Of The Growth Factors Of This Market:
- Rising incidence of ovarian cancer and the increasing number of women in the reproductive age group are driving the growth of this market.
- Increasing awareness about ovarian cancer and its symptoms among women is also driving the growth of this market.
- The Ovarian Cancer Drugs market is fragmented with a large number of players operating in it, which makes it difficult for new entrants to enter into this market.
- The Ovarian Cancer Drugs market has been witnessing an increase in mergers and acquisitions.
Industry Growth Insights published a new data on “Ovarian Cancer Drugs Market”. The research report is titled “Ovarian Cancer Drugs Market research by Types (Alkylating Agents, Mitotic Inhibitors, Antirheumatics, Antipsoriatics, VEGF/VEGFR Inhibitors, PARP Inhibitors, Antineoplastics, Others), By Applications (Hospital Pharmacies, Drug Stores, Online Pharmacies, Others), By Players/Companies Allergan plc, Pfizer, Inc., Merck KGaA, AstraZeneca, F. Hoffmann-La Roche AG, Johnson & Johnson, Syndax Pharmaceuticals, Inc., Clovis Oncology”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Ovarian Cancer Drugs Market Research Report
By Type
Alkylating Agents, Mitotic Inhibitors, Antirheumatics, Antipsoriatics, VEGF/VEGFR Inhibitors, PARP Inhibitors, Antineoplastics, Others
By Application
Hospital Pharmacies, Drug Stores, Online Pharmacies, Others
By Companies
Allergan plc, Pfizer, Inc., Merck KGaA, AstraZeneca, F. Hoffmann-La Roche AG, Johnson & Johnson, Syndax Pharmaceuticals, Inc., Clovis Oncology
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Ovarian Cancer Drugs Market Report Segments:
The global Ovarian Cancer Drugs market is segmented on the basis of:
Types
Alkylating Agents, Mitotic Inhibitors, Antirheumatics, Antipsoriatics, VEGF/VEGFR Inhibitors, PARP Inhibitors, Antineoplastics, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Drug Stores, Online Pharmacies, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan plc
- Pfizer, Inc.
- Merck KGaA
- AstraZeneca
- F. Hoffmann-La Roche AG
- Johnson & Johnson
- Syndax Pharmaceuticals, Inc.
- Clovis Oncology
Highlights of The Ovarian Cancer Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Alkylating Agents
- Mitotic Inhibitors
- Antirheumatics
- Antipsoriatics
- VEGF/VEGFR Inhibitors
- PARP Inhibitors
- Antineoplastics
- Others
- By Application:
- Hospital Pharmacies
- Drug Stores
- Online Pharmacies
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ovarian Cancer Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Ovarian cancer drugs are medications used to treat ovarian cancer. These drugs can help to shrink or stop the growth of tumors in the ovaries. Some ovarian cancer drugs may also help to prevent new tumors from forming.
Some of the key players operating in the ovarian cancer drugs market are Allergan plc, Pfizer, Inc., Merck KGaA, AstraZeneca, F. Hoffmann-La Roche AG, Johnson & Johnson, Syndax Pharmaceuticals, Inc., Clovis Oncology.
The ovarian cancer drugs market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Ovarian Cancer Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Ovarian Cancer Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Ovarian Cancer Drugs Market - Supply Chain
4.5. Global Ovarian Cancer Drugs Market Forecast
4.5.1. Ovarian Cancer Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Ovarian Cancer Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Ovarian Cancer Drugs Market Absolute $ Opportunity
5. Global Ovarian Cancer Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Ovarian Cancer Drugs Market Size and Volume Forecast by Type
5.3.1. Alkylating Agents
5.3.2. Mitotic Inhibitors
5.3.3. Antirheumatics
5.3.4. Antipsoriatics
5.3.5. VEGF/VEGFR Inhibitors
5.3.6. PARP Inhibitors
5.3.7. Antineoplastics
5.3.8. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Ovarian Cancer Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Ovarian Cancer Drugs Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Drug Stores
6.3.3. Online Pharmacies
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Ovarian Cancer Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Ovarian Cancer Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Ovarian Cancer Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Ovarian Cancer Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Ovarian Cancer Drugs Demand Share Forecast, 2019-2026
9. North America Ovarian Cancer Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Ovarian Cancer Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Ovarian Cancer Drugs Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Drug Stores
9.4.3. Online Pharmacies
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Ovarian Cancer Drugs Market Size and Volume Forecast by Type
9.7.1. Alkylating Agents
9.7.2. Mitotic Inhibitors
9.7.3. Antirheumatics
9.7.4. Antipsoriatics
9.7.5. VEGF/VEGFR Inhibitors
9.7.6. PARP Inhibitors
9.7.7. Antineoplastics
9.7.8. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Ovarian Cancer Drugs Demand Share Forecast, 2019-2026
10. Latin America Ovarian Cancer Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Ovarian Cancer Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Ovarian Cancer Drugs Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Drug Stores
10.4.3. Online Pharmacies
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Ovarian Cancer Drugs Market Size and Volume Forecast by Type
10.7.1. Alkylating Agents
10.7.2. Mitotic Inhibitors
10.7.3. Antirheumatics
10.7.4. Antipsoriatics
10.7.5. VEGF/VEGFR Inhibitors
10.7.6. PARP Inhibitors
10.7.7. Antineoplastics
10.7.8. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Ovarian Cancer Drugs Demand Share Forecast, 2019-2026
11. Europe Ovarian Cancer Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Ovarian Cancer Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Ovarian Cancer Drugs Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Drug Stores
11.4.3. Online Pharmacies
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Ovarian Cancer Drugs Market Size and Volume Forecast by Type
11.7.1. Alkylating Agents
11.7.2. Mitotic Inhibitors
11.7.3. Antirheumatics
11.7.4. Antipsoriatics
11.7.5. VEGF/VEGFR Inhibitors
11.7.6. PARP Inhibitors
11.7.7. Antineoplastics
11.7.8. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Ovarian Cancer Drugs Demand Share, 2019-2026
12. Asia Pacific Ovarian Cancer Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Ovarian Cancer Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Ovarian Cancer Drugs Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Drug Stores
12.4.3. Online Pharmacies
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Ovarian Cancer Drugs Market Size and Volume Forecast by Type
12.7.1. Alkylating Agents
12.7.2. Mitotic Inhibitors
12.7.3. Antirheumatics
12.7.4. Antipsoriatics
12.7.5. VEGF/VEGFR Inhibitors
12.7.6. PARP Inhibitors
12.7.7. Antineoplastics
12.7.8. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Ovarian Cancer Drugs Demand Share, 2019-2026
13. Middle East & Africa Ovarian Cancer Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Ovarian Cancer Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Ovarian Cancer Drugs Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Drug Stores
13.4.3. Online Pharmacies
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Ovarian Cancer Drugs Market Size and Volume Forecast by Type
13.7.1. Alkylating Agents
13.7.2. Mitotic Inhibitors
13.7.3. Antirheumatics
13.7.4. Antipsoriatics
13.7.5. VEGF/VEGFR Inhibitors
13.7.6. PARP Inhibitors
13.7.7. Antineoplastics
13.7.8. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Ovarian Cancer Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Ovarian Cancer Drugs Market: Market Share Analysis
14.2. Ovarian Cancer Drugs Distributors and Customers
14.3. Ovarian Cancer Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Allergan plc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer, Inc.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Merck KGaA
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. AstraZeneca
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. F. Hoffmann-La Roche AG
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Johnson & Johnson
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Syndax Pharmaceuticals, Inc.
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Clovis Oncology
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
